Home > Neurology > MTIS 2020 > Contents > Long-term efficacy and safety of fremanezumab in treatment-resistant migraine

Long-term efficacy and safety of fremanezumab in treatment-resistant migraine

Presented By
Dr M. Ashina
Conference
MTIS 2020
Trial
Phase 3, FOCUS
Fremanezumab, a fully-humanised monoclonal antibody that selectively targets calcitonin gene-related peptide (CGRP), demonstrated sustained efficacy up to 6 months and long-term tolerability in patients with episodic or chronic migraine who had an inadequate response to 2-4 classes of prior migraine preventive medications [1]. The double-blind, placebo-controlled, phase 3b FOCUS trial included patients with episodic or chronic migraine, who had an inadequate response to 2-4 prior classes of migraine preventive medications. The study included a 12-week double-blind period and 12-week open-label extension phase. Patients were initially randomised to: quarterly fremanezumab: 675 mg in month 1 and placebo in months 2 and 3; monthly fremanezumab: 675 mg in patients with chronic migraine and 225 mg in patients with episodic migraine in mo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on